Anne M. VanLent
Independent DirectorMs. Anne M. VanLent has been Independent Director of Trevi Therapeutics, Inc. since October 10, 2018. She had been a Director of ObsEva SA since May 28, 2021 until 2023. She founded AMV Advisors in 2008 and serves as its President. She has extensive leadership and finance past work and has extensive prior work as a Board Member in the life sciences industry. She has done prior working with emerging growth life sciences companies. She served as the President of AMV Associates from March 1994 to August 1997. She served as Chief Financial Officer and Senior Vice President of The Liposome Company, Inc., from 1985 to 1993 and also served as its Executive. She served as an Executive Vice President and Treasurer of Barrier Therapeutics, Inc., from May 2002 to April 30, 2008. She served as Chief Financial Officer and Executive Vice President of Trophix Pharmaceuticals Inc. She served as the Chief Financial Officer of Barrier Therapeutics, Inc., from May 2002 to April 30, 2008 and also served as its Principal Accounting Officer. From July 1997 to October 2001, she served as an Executive Vice President of Portfolio Management at Sarnoff Corporation. She serves as a Director of Trevi Pharmaceuticals, Inc. She has been an Independent Director of Applied Genetic Technologies Corporation since August 18, 2016. From May 2013 until June 2020, she served as a Director of Vaxart, Inc. She served as an Independent Director at Aviragen Therapeutics, Inc. (Biota Pharmaceuticals, Inc.), since May 2013 and served as its Lead Director since November 2015. She serves as a Director of a Private Fuel Cell Development Company. She served as a Director of Novelion Therapeutics Inc. from November 29, 2016 to June 28, 2017. She served as a Director at Aegerion Pharmaceuticals, Inc., from April 26, 2013 to November 29, 2016. She served as Independent Director at Ocera Therapeutics, Inc. since March 2011 until December 11, 2017. Ms. VanLent also served as a member of the board of directors and audit committee chair of Applied Genetics Technologies Corporation, a publicly traded biotechnology company, from August 2016 until it was acquired by Syncona Limited in December 2022. She served as a Director of Onconova Therapeutics, Inc. from June 2013 to May 18, 2016. From March 2013 to June 2017 she served as a Director of Novelion Pharmaceuticals, Inc. She served as a Director of E-Vue Inc. and Tranzyme Pharma, Inc. She served as a Director of Integra Lifesciences Holdings Corporation (Integra Life Sciences Holdings, Inc.) from December 20, 2004 to May 22, 2013; Tranzyme, Inc., since March 2011; i-STAT Corp., since July 1999 and Penwest Pharmaceuticals Co., from December 1998 to 2010. She received a B.A. in Physics from Mount Holyoke College and did graduate work in Biophysics. She served as a Director of International AIDS Vaccine Initiative, Inc.
Positions
- Company NameTrevi Therapeutics, Inc.Stock CodeTRVIPositionIndependent DirectorColleagues
- JLJennifer L. GoodCo-Founder, CEO, President, & Director
- DPDavid P. MeekerIndependent Chairman of the Board
- JVJames V. CassellaChief Development Officer
- FSFarrell SimonChief Commercial Officer
- TRThomas R. SciasciaCo-Founder & Chief Scientific Officer
- DCDavid C. HastingsChief Financial Officer & Principal Financial Officer
- MTMichael Thomas HeffernanIndependent Director
- JBJeffrey BernhardMember of Clinical Advisory Board
